The GLP-1 Side-Effect & Progress Tracker on this site is designed to help you log exactly this kind of information over time
Shao, Y., Chen, S., Li, H., Tang, Q
In March 2026, Structure reported 44-week topline data from the ACCESS II Phase 2 study, showing placebo-adjusted weight loss of up to 16.3%, which the company described as the highest efficacy demonstrated among oral GLP-1 receptor agonists at that time point
Gallbladder issues, including gallstones, may occur, especially during rapid weight loss
Losing abdominal fat restores lung mechanics
Ulises Ahumada-Castro, [email protected] These authors have contributed equally to this work Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers